Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

22 brokers have issued 1 year price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $575.00 to $970.00. On average, they expect the company's share price to reach $766.81 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

Regeneron Pharmaceuticals' stock was trading at $631.52 at the start of the year. Since then, REGN stock has increased by 16.6% and is now trading at $736.23.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $15.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.81 by $5.56. The biopharmaceutical company earned $3.45 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 31.16% and a net margin of 39.17%. Regeneron Pharmaceuticals's quarterly revenue was up 50.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.68 earnings per share.
Read the conference call transcript.

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.71%), Vanguard Group Inc. (7.94%), State Street Corp (4.64%), Price T Rowe Associates Inc. MD (1.61%), Putnam Investments LLC (1.01%) and Bank of New York Mellon Corp (0.94%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $736.23.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $80.18 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.

The company employs 10,368 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.